National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 6 of 1991)

Overview

The National Health Act 1953, as amended, includes provisions for the regulation of pharmaceutical benefits within Australia. One specific legislative instrument, the Pharmaceutical Benefits Declaration under Subsection 85(2AA), was introduced to address the need for periodic updates to the list of pharmaceutical benefits. This instrument allows the Minister for Health, through their delegate, to remove certain drugs and medicinal preparations from the list of substances covered by the Act. Enacted by the Commonwealth of Australia, the policy objective behind this declaration is to ensure the Pharmaceutical Benefits Scheme (PBS) remains current and effective by removing medications that no longer meet the criteria for inclusion. This particular declaration, which came into operation on 1 August 1991, specifies the removal of certain drugs from the PBS list, ensuring that the scheme is responsive to changes in medical needs and practices.

Scope and Application

The National Health Act 1953, as amended through this legislative instrument, applies to the regulation of pharmaceutical benefits within the Commonwealth of Australia. Specifically, this legislative instrument pertains to the declaration of certain drugs and medicinal preparations that will cease to be subject to Part VII of the Act, which deals with the Pharmaceutical Benefits Scheme. This change impacts entities such as pharmaceutical manufacturers, suppliers, and distributors who are involved in the supply of these specific drugs. The geographic reach of this Act is national, applying uniformly across the Commonwealth of Australia. Exclusions or exemptions from this legislative instrument are narrowly defined within the Schedule, which lists the specific drugs and preparations affected by this declaration. Any broader application or restriction of these provisions can be further delineated through subordinate instruments issued under the authority of the Act, which may provide additional details or clarifications to the provisions contained within the primary legislation.

Key Provisions

The main operative sections of this Declaration under subsection 85(2AA) of the National Health Act 1953 (section 85) specify that certain drugs and medicinal preparations will cease to be subject to Part VII of the Act, which pertains to the Pharmaceutical Benefits Scheme. The Declaration, signed by Fiona Margaret Howarth, lists specific drugs including Debrisoquine Sulphate, Difenoxin Hydrochloride with Atropine Sulphate, Flucytosine, Glucose, Anhydrous with Sodium Chloride, Potassium Chloride, Citric Acid, and Sodium Citrate, and Procarbazine Hydrochloride, which will no longer be covered under the Pharmaceutical Benefits Scheme as of 1 August 1991 (section 2). The Declaration is effective from this date and serves to amend the list of drugs and preparations that are eligible for subsidies under the Pharmaceutical Benefits Scheme. The obligations and requirements imposed by this Act primarily concern the Pharmaceutical Benefits Advisory Committee, whose advice is sought by the Principal Advisor prior to making such a Declaration. The Principal Advisor must follow the advice of the Committee, ensuring that the decision to remove certain drugs from the Pharmaceutical Benefits Scheme is informed by expert medical and pharmaceutical input. Furthermore, the Declaration itself must be published and come into effect on the specified date, ensuring that all stakeholders are informed of the changes. Breach of the provisions set out in the National Health Act 1953 may result in civil or criminal consequences, depending on the nature of the breach. While the specific penalties are not detailed within this Declaration, it is pertinent to note that under the broader Act, unauthorised actions or improper administration of the Pharmaceutical Benefits Scheme could attract fines and other legal repercussions. For instance, section 120 of the Act outlines penalties for fraudulent conduct related to the Scheme, which can include substantial fines and imprisonment. The precise penalties would be determined based on the specific nature and severity of the breach, as outlined in the broader legislative framework.